3B Pharmaceuticals GmbH has discovered conjugates comprising peptides targeting urokinase plasminogen activator surface receptor (uPAR) covalently linked to a chelating moiety through a linker. They are reported to be useful for the diagnosis and/or treatment of cancer.

Sanofi SA has disclosed compounds reported to be useful for the treatment of cancer as well as viral and bacterial infections.

Monte Rosa Therapeutics Inc. has synthesized molecular glue degraders comprising a E3 ubiquitin-protein ligase binding moiety coupled to a cyclin-dependent kinase 2 (CDK2)-targeting moiety acting as cyclin-dependent kinase 2 (CDK2) degradation inducers potentially useful for the treatment of cancer.

Kyoto University has identified new spermidine derivatives reported to be useful for the treatment of cancer and infections.

Prelude Therapeutics Inc. has prepared and tested new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and SMARCA4-targeting moiety through a linker.

A Gilead Sciences Inc. patent describes new compounds acting as pyroptosis inducers reported to be useful for the treatment of HIV infections.

Chinese Academy of Sciences researchers have patented heptanoate compounds reported to be useful for the treatment of amyotrophic lateral sclerosis, Alzheimer’s, Parkinson’s and Huntington’s disease.

Touchstone Innovations Ltd. has described peptide hormone analogues acting as gastric inhibitory polypeptide receptor (GIPR) agonists reported to be useful for the treatment of obesity.

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has divulged antibody-drug conjugates (ADCs) comprising antibodies targeting human mucin-17 (MUC17) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.